Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 07 2020 - 4:11PM
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global
biopharmaceutical company pioneering targeted C3 therapies, today
announced that it has commenced an underwritten public offering of
7,000,000 shares of its common stock. All of the shares are being
offered by Apellis. In addition, Apellis expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of its common stock sold in the public offering.
Citigroup, J.P. Morgan and Evercore ISI are acting as joint
book-running managers for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The shares are being offered by Apellis pursuant to an
automatically effective shelf registration statement that was filed
with the Securities and Exchange Commission (“SEC”) on January 7,
2020.
This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering is expected to be filed with
the SEC and, if and when filed, copies of the preliminary
prospectus supplement relating to the offering may be obtained for
free by visiting the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may also be obtained by contacting: Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: 1-800-831-9146; J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, NY 10055, telephone: (888)
474-0200, or email: ecm.prospectus@evercore.com. The final terms of
the offering will be disclosed in a final prospectus supplement to
be filed with the SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apellis Apellis Pharmaceuticals, Inc. is
a global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. By pioneering targeted C3 therapies, we
aim to develop best-in-class and first-in-class therapies for a
broad range of debilitating diseases that are driven by
uncontrolled or excessive activation of the complement cascade,
including those within hematology, ophthalmology, and nephrology.
For more information, please visit http://apellis.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects, as well as any other statements regarding matters
that are not historical facts, may constitute “forward-looking
statements” within the meaning of The Private Securities Litigation
Reform Act of 1995. These statements include, but are not limited
to, statements relating to the company’s anticipated public
offering. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all, uncertainties inherent in the
initiation of future clinical trials and other factors discussed in
the “Risk Factors” section of the preliminary prospectus supplement
to be filed with the SEC, Apellis’ Quarterly Report on Form 10-Q
filed with the SEC on November 5, 2019, and the risks described in
other filings that Apellis may make with the SEC. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Media Contact: Tracy Vineis media@apellis.com
617.420.4839
Investor Contact: Sam Martin / Maghan
Meyers Argot Partnerssam@argotpartners.com
/ maghan@argotpartners.com 212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Oct 2023 to Oct 2024